Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Determination of epithelial growth factor receptor mutations in circulatory tumour cells from non-small cell lung cancer patients isolated using a novel microfluidic device (2022)
Thesis
Ogidi, N. O. Determination of epithelial growth factor receptor mutations in circulatory tumour cells from non-small cell lung cancer patients isolated using a novel microfluidic device. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4270004

Patients with epidermal growth factor receptor (EGFR) sensitizing mutations in non small cell lung cancer (NSCLC) receive benefit from Tyrosine Kinase inhibitors. Accurate selection of patients before treatment is highly dependent on precise molecula... Read More about Determination of epithelial growth factor receptor mutations in circulatory tumour cells from non-small cell lung cancer patients isolated using a novel microfluidic device.

Arginine deprivation with pegylated Arginine Deiminase in patients with Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial (2016)
Journal Article
Szlosarek, P. W., Steele, J. P., Nolan, L., Gilligan, D., Taylor, P., Spicer, J., Lind, M., Mitra, S., Shamash, J., Phillips, M. M., Luong, P., Payne, S., Hillman, P., Ellis, S., Szyszko, T., Dancey, G., Butcher, L., Beck, S., Avril, N. E., Thomson, J., …Hackshaw, A. (2017). Arginine deprivation with pegylated Arginine Deiminase in patients with Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncology, 3(1), 58-66. https://doi.org/10.1001/jamaoncol.2016.3049

Importance: Preclinical studies show that arginine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20)... Read More about Arginine deprivation with pegylated Arginine Deiminase in patients with Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.